Loading...

PerCP/Cyanine5.5 anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1-5_PerCPCyanine55_CD4_Antibody_082418
C57BL/6 mouse splenocytes were stained with CD3e FITC and CD4 (Clone GK1.5) PerCP/Cyanine5.5 (left), or rat IgG2b, κ PerCP/Cyanine5.5 isotype control (right).
  • GK1-5_PerCPCyanine55_CD4_Antibody_082418
    C57BL/6 mouse splenocytes were stained with CD3e FITC and CD4 (Clone GK1.5) PerCP/Cyanine5.5 (left), or rat IgG2b, κ PerCP/Cyanine5.5 isotype control (right).
See PerCP/Cyanine5.5 spectral data
Cat # Size Price Quantity Check Availability Save
100433 25 µg $118
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100434 100 µg $323
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical data sheet

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PerCP/Cyanine5.5 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl. It is recommended that the reagent be titrated for optimal performance for each application.

* PerCP/Cyanine5.5 has a maximum absorption of 482 nm and a maximum emission of 690 nm.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, immunoprecipitation1,2, and spatial biology (IBEX)12,13. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Additional Product Notes
BioLegend is in the process of converting the name PerCP/Cy5.5 to PerCP/Cyanine5.5. The dye molecule remains the same, so you should expect the same quality and performance from our PerCP/Cyanine5.5 products. Contact Technical Service if you have any questions.
Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
  12. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  13. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Tello‐Lafoz M, et al. 2017. Sci Rep. . 10.1038/s41598-017-16370-w. PubMed
  2. LaMothe RA et al. 2018. Front Immunol. 0.570138889 . PubMed
  3. Anderson AM, et al. 2018. J Immunol. 200:2057. PubMed
  4. Song P, et al. 2018. Int J Mol Med. 41:935. PubMed
  5. Webster P, et al. 2018. Nat Commun. 9:2649. PubMed
  6. Abhyankar MM, et al. 2018. NPJ Vaccines. 3:22. PubMed
  7. Aurélien Trompette et al. 2018. Immunity. 48(5):992-1005 . PubMed
  8. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  9. Fan MY et al. 2018. Cell reports. 25(5):1204-1213 . PubMed
  10. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  11. Romain Bouziat et al. 2018. Cell host & microbe. 24(5):677-688 . PubMed
  12. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  13. Nagai Y, et al. 2019. Front Immunol. 10:174. PubMed
  14. Perry JSA, et al. 2018. Immunity. 48:923. PubMed
  15. Kong XF, et al. 2018. Nat Immunol. 19:973. PubMed
  16. Li X, et al. 2019. Mol Med Rep. 19:4195. PubMed
  17. Bommareddy PK, et al. 2019. J Biol Methods. 6:2. PubMed
  18. Iwata TN, et al. 2018. Mol Cancer Ther. 17:1494. PubMed
  19. Sasaki K, et al. 2019. Nat Commun. 10:3878. PubMed
  20. Di Mitri D, et al. 2019. Cell Rep. 28:2156. PubMed
  21. Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed
  22. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  23. Kim MY, et al. 2017. Plant Biotechnol J. 1.729166667. PubMed
  24. Muchenditsi A, et al. 2017. Am J Physiol Gastrointest Liver Physiol. 313:G39. PubMed
  25. Toubai T, et al. 2017. Blood Adv. 1.095138889. PubMed
  26. Namkoong H, et al. 2018. PLoS Pathog. 14:e1006955. PubMed
  27. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  28. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  29. Wang F, et al. 2019. MAbs. 12:1685350. PubMed
  30. Field CS, et al. 2020. Cell Metab. 31:422. PubMed
  31. Miao L, et al. 2020. Theranostics. 0.7625. PubMed
  32. Grødeland G, et al. 2020. Front Immunol. 11:431. PubMed
  33. Suhail A, et al. 2019. Cell Rep. 29:3522. PubMed
  34. Wu HL, et al. 2018. J Immunol. 200:49. PubMed
  35. Frodermann V, et al. 2019. Nat Med. 25:1761. PubMed
  36. Liu H, et al. 2020. Cancer Cell. 37(3):324-339. PubMed
  37. Rivadeneira DB, et al. 2020. Immunity. 51(3):548-560. PubMed
  38. Pham THM, et al. 2020. Cell Host & Microbe. 27(1):54-67.e5.. PubMed
  39. Diaz–Salazar C, et al. 2020. Cell Rep. 32:108186. PubMed
  40. Bartolacci C, et al. 2018. Cancer Immunol Res. 1.281944444. PubMed
  41. Chen J, et al. 2014. Cell Res. 24:1050. PubMed
  42. Chen Z, et al. 2014. Cancer Immunol Res. 2:911. PubMed
  43. Pandey S, et al. 2014. J Immunol. 193:3632. PubMed
  44. Acker A, et al. 2014. PLoS One. 9:110015. PubMed
  45. Kim Y, et al. 2015. PLoS One. 10:120294. PubMed
  46. Flaherty S, Reynolds J 2015. J Vis Exp. 98: 52739. PubMed
  47. Jeon Y, et al. 2015. PLoS One. 10: e0139845. PubMed
  48. Kawano H, et al. 2016. Int Immunol. 28: 489 - 501. PubMed
  49. Lee L, et al. 2016. PLoS One. 11:e0167693. PubMed
  50. Bansal K, et al. 2017. Nat Immunol. 18:263-273. PubMed
  51. Furuta Y, et al. 2017. PLoS One. 12(2):e0172509. PubMed
  52. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed
  53. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
  54. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  55. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
  56. Pack AD, et al. 2021. Cell Reports. 36:109586. PubMed
  57. Noah AC, et al. 2020. J Appl Physiol (1985). 473:128. PubMed
  58. Zeng F, et al. 2021. J Invest Dermatol. 596:141. PubMed
  59. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  60. Wei H, et al. 2021. Malar J. 20:89. PubMed
  61. Wang H, et al. 2021. Malar J. 20:249. PubMed
  62. Panea C, et al. 2021. Commun Biol. 4:913. PubMed
  63. Li Y, et al. 2020. Front Cell Dev Biol. 8:604021. PubMed
  64. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  65. Mao FY, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:395. PubMed
  66. Sugita J, et al. 2021. Nat Commun. 12:1910. PubMed
  67. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  68. Hoffmann A, et al. 2021. EBioMedicine. 71:103568. PubMed
  69. He S, et al. 2021. Front Pharmacol. 12:743837. PubMed
  70. Tsai SJ, et al. 2021. J Biol Chem. 297:101266. PubMed
  71. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  72. Li H, et al. 2021. Protein Cell. Online ahead of print. PubMed
  73. Ohtsuka J, et al. 2021. iScience. Online ahead of print. PubMed
  74. Vijay R, et al. 2020. Nat Immunol. 21:790. PubMed
  75. Reese B, et al. 2020. J Immunol. 205:3218. PubMed
  76. Vijay R, et al. 2021. J Exp Med. 218:. PubMed
  77. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  78. Xing Y, et al. 2022. Cancer Lett. 529:100. PubMed
  79. Vogel A, et al. 2022. Cell Rep. 38:110420. PubMed
  80. Miyauchi E, et al. 2020. Nature. 585:102. PubMed
  81. Srey MT, et al. 2020. PLoS Negl Trop Dis. 14:e0008842. PubMed
  82. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  83. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  84. Li H, et al. 2021. Front Immunol. 12:739605. PubMed
  85. Snyder LM, et al. 2021. PLoS Pathog. 17:e1009970. PubMed
  86. Sun Y, et al. 2022. Nat Commun. 13:3916. PubMed
  87. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  88. Mei S, et al. 2022. Front Immunol. 13:911164. PubMed
  89. Zheng Y, et al. 2022. Transl Res. :. PubMed
  90. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  91. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  92. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  93. Vogel A, et al. 2022. STAR Protoc. 3:101653. PubMed
  94. Tomala J, et al. 2020. Methods Mol Biol. 2111:101. PubMed
  95. White MPJ, et al. 2020. Front Immunol. 11:1830. PubMed
  96. Chen HL, et al. 2021. Pharm Biol. 59:134. PubMed
  97. Gawish R, et al. 2022. Elife. 11:. PubMed
  98. Yang X, et al. 2020. Blood Sci. 2:89. PubMed
  99. Ahn SH, et al. 2022. Front Endocrinol (Lausanne). 13:846226. PubMed
  100. Wang Y, et al. 2022. J Control Release. 349:118. PubMed
  101. Zhao F, et al. 2022. Front Immunol. 13:873720. PubMed
  102. Gawish R, et al. 2022. Elife. 11:. PubMed
  103. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
  104. Zhu J, et al. 2022. Research (Wash D C). 2022:9816272. PubMed
  105. Hu X, et al. 2022. EBioMedicine. 86:104333. PubMed
  106. Ding D, et al. 2023. J Med Chem. 66:1467. PubMed
  107. Glaubitz J, et al. 2023. Gut. :. PubMed
  108. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  109. Arimoto KI, et al. 2023. Nat Commun. 14:251. PubMed
  110. Wang R, et al. 2023. NPJ Vaccines. 8:6. PubMed
  111. Fueyo-González F, et al. 2022. Immunity. 55:459. PubMed
  112. Akhtar MN, et al. 2022. MBio. 13:e0330921. PubMed
  113. Wei X, et al. 2022. Cell Rep. 40:111313. PubMed
  114. Zhao Q, et al. 2023. Signal Transduct Target Ther. 8:40. PubMed
  115. Liu N, et al. 2023. Cell Death Dis. 14:170. PubMed
  116. Li G, et al. 2023. Cell Death Dis. 14:185. PubMed
  117. Bhaskar A, et al. 2023. iScience. 26:106644. PubMed
  118. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  119. Xie J, et al. 2023. Mol Ther Oncolytics. 29:61. PubMed
  120. Milighetti M, et al. 2023. iScience. 26:106937. PubMed
  121. Lin CH, et al. 2023. iScience. 26:106904. PubMed
RRID
AB_893330 (BioLegend Cat. No. 100433)
AB_893324 (BioLegend Cat. No. 100434)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
How stable is PerCP/Cyanine5.5 tandem as compared to PerCP alone?

PerCP/Cyanine5.5 is quite photostable and also better than PerCP alone in withstanding fixation.

Go To Top Version: 2    Revision Date: 08/24/2018

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account